JP2017077232A - Method for eliminating genetic information of non-enveloped virus - Google Patents
Method for eliminating genetic information of non-enveloped virus Download PDFInfo
- Publication number
- JP2017077232A JP2017077232A JP2015217969A JP2015217969A JP2017077232A JP 2017077232 A JP2017077232 A JP 2017077232A JP 2015217969 A JP2015217969 A JP 2015217969A JP 2015217969 A JP2015217969 A JP 2015217969A JP 2017077232 A JP2017077232 A JP 2017077232A
- Authority
- JP
- Japan
- Prior art keywords
- ethanol
- salt
- weight
- citric acid
- lactic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 244000309711 non-enveloped viruses Species 0.000 title claims abstract description 24
- 230000002068 genetic effect Effects 0.000 title claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 194
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000002360 preparation method Methods 0.000 claims abstract description 58
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000004310 lactic acid Substances 0.000 claims abstract description 24
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- -1 fatty acid ester Chemical class 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229920000223 polyglycerol Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 241001263478 Norovirus Species 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000005260 corrosion Methods 0.000 description 6
- 230000007797 corrosion Effects 0.000 description 6
- 239000005708 Sodium hypochlorite Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000007721 medicinal effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229940070765 laurate Drugs 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 241000702247 Reoviridae Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
本発明は、ノンエンベロープウイルスの不活化に関する。 The present invention relates to inactivation of non-enveloped viruses.
厚生労働省によると、冬の急性胃腸炎患者の１０分の１はノロウイルス感染によるとされている。ノロウイルスの感染経路はほとんどが経口であり、食品取扱者や調理器具からの二次汚染を防止するとの観点で、これらの表面に存在するノロウイルスの失活化または不活化が重要である。
厚生労働省によると、ノロウイルスの失活化には消毒用エタノールや逆性石鹸は効果がなく、次亜塩素酸ナトリウム水溶液がノロウイルス失活化に効果があるとされる。According to the Ministry of Health, Labor and Welfare, one tenth of patients with acute gastroenteritis in winter is due to norovirus infection. Most of the infection routes of norovirus are oral, and from the viewpoint of preventing secondary contamination from food handlers and cooking utensils, it is important to inactivate or inactivate norovirus present on these surfaces.
According to the Ministry of Health, Labor and Welfare, disinfecting ethanol and reverse soap are not effective in inactivating norovirus, and sodium hypochlorite aqueous solution is effective in inactivating norovirus.
しかし、次亜塩素酸ナトリウム水溶液は特有の臭気が強く、皮膚に付着して肌荒れを起こす、衣服や絨毯を脱色してしまう等の問題点が存在する。また、酸と混合すると塩素ガスを発生し、中毒症状を起こすこともあり、危険な場合もある。
一方、エタノールは酒類等の食品に含まれる成分のため安全性が高いが、上記のように単独ではノロウイルスをはじめとするエンベロープを持たないウイルス、すなわちノンエンベロープウイルスを不活化する効果は期待できない。However, the sodium hypochlorite aqueous solution has a strong odor and causes problems such as adhesion to the skin and rough skin, and discoloration of clothes and carpets. In addition, when mixed with acid, it generates chlorine gas, which may cause poisoning and may be dangerous.
On the other hand, ethanol is highly safe because it is a component contained in foods such as alcoholic beverages, but it cannot be expected to inactivate viruses having no envelope such as norovirus, that is, non-enveloped viruses alone, as described above.
本発明者らはこれまでに、エタノール、リン酸、グリセリン脂肪酸エステルおよびポリグリセリン脂肪酸エステルを含み、かつｐＨが２．５〜５．０の範囲にある水溶液からなる組成物によるカリシウイルス不活化方法を開示している（特許文献１参照）。この発明は、エタノールを酸性に調整することで抗カリシウイルス活性が向上することを見出してなされたものであり、タンパク質存在下でもカリシウイルスを不活化できることに特長がある。
また、リン酸以外の成分を用いるものとして、エタノールまたはイソプロピルアルコール、乳酸、クエン酸および亜鉛含有化合物を含有する消毒剤が開示されている（特許文献２参照 ）。The present inventors have so far disclosed a method for inactivating calicivirus by a composition comprising an aqueous solution containing ethanol, phosphoric acid, glycerin fatty acid ester and polyglycerin fatty acid ester and having a pH in the range of 2.5 to 5.0. Is disclosed (see Patent Document 1). The present invention has been made by finding that anti-calicivirus activity is improved by adjusting ethanol to be acidic, and is characterized in that calicivirus can be inactivated even in the presence of protein.
In addition, disinfectants containing ethanol or isopropyl alcohol, lactic acid, citric acid and zinc-containing compounds have been disclosed as components other than phosphoric acid (see Patent Document 2).
しかし、このようなエタノール製剤では、効果の強化を狙って有効成分の濃度を高くしすぎると、器具等への使用後に有効成分による金属腐食、べたつき、白残り等が生じることがあり、抗ウイルス効果とこれらの好ましくない事象の発生可能性とのバランスをとることが難しくなる。
このため、バランスよくノンエンベロープウイルスを不活化できる方法が求められている。However, in such ethanol preparations, if the concentration of the active ingredient is increased too much in order to enhance the effect, metal corrosion, stickiness, white residue, etc. may occur due to the active ingredient after use in an appliance, etc. It becomes difficult to balance the effects with the likelihood of these undesirable events.
For this reason, there is a need for a method that can inactivate non-enveloped viruses in a balanced manner.
本発明の課題は、使用後に固形分の残存によるべたつき、白残り等の好ましくない事象が発生する可能性を抑えた条件で、ノンエンベロープウイルスの遺伝情報を担うＤＮＡまたはＲＮＡを消失させる方法、すなわちノンエンベロープウイルスを死滅させる方法、または該方法に用い得るエタノール製剤を提供することにある。 The subject of the present invention is a method for erasing DNA or RNA carrying genetic information of a non-enveloped virus under conditions that suppress the possibility of occurrence of undesirable events such as stickiness due to residual solids and white residue after use, that is, The object is to provide a method for killing non-enveloped viruses, or an ethanol preparation that can be used in the method.
本発明者らは、エタノール製剤中の特定の有効成分の含有量および含有比率等を特定の条件とした場合、ノンエンベロープウイルスの遺伝情報を担うＤＮＡまたはＲＮＡが顕著なレベルで消失することを見出し、本発明を完成するに至った。
すなわち、本発明は以下の（１）または（２）に関する。The present inventors have found that DNA or RNA carrying non-enveloped virus genetic information disappears at a remarkable level when the content and content ratio of a specific active ingredient in an ethanol preparation are specified conditions. The present invention has been completed.
That is, the present invention relates to the following (1) or (2).
（１）各有効成分の含有量およびｐＨが以下（ａ）〜（ｅ）であるエタノール製剤をノンエンベロープウイルスと接触させることを特徴とする、ノンエンベロープウイルスの遺伝情報を消失させる方法。
（ａ）乳酸またはその塩の含有量が、乳酸として１．０〜１．８重量％である
（ｂ）クエン酸またはその塩の含有量が、クエン酸として０．２〜０．５重量％である
（ｃ）乳酸またはその塩とクエン酸またはその塩の重量比が、乳酸とクエン酸として４：１である
（ｄ）ｐＨが、ｐＨ３〜４である
（ｅ）エタノール濃度が、６５重量％以上、７５重量％未満である(1) A method for eliminating genetic information of a non-enveloped virus, which comprises contacting an ethanol preparation having the content and pH of each active ingredient below (a) to (e) with the non-enveloped virus.
(A) The content of lactic acid or a salt thereof is 1.0 to 1.8% by weight as lactic acid. (B) The content of citric acid or a salt thereof is 0.2 to 0.5% by weight as citric acid. (C) The weight ratio of lactic acid or its salt to citric acid or its salt is 4: 1 as lactic acid and citric acid (d) pH is pH 3-4 (e) Ethanol concentration is 65 weight % Or more and less than 75% by weight
（２）エタノール製剤が、さらにポリグリセリン脂肪酸エステルを含有するエタノール製剤である、上記（１）の方法。(2) The method according to (1) above, wherein the ethanol preparation is an ethanol preparation further containing a polyglycerol fatty acid ester.
本発明により、使用後に固形分の残存によるべたつき、白残り等が発生しにくい条件で、ノンエンベロープウイルスの確実な不活化につながる遺伝情報の消失方法および該方法に用い得るエタノール製剤を提供することができる。係る方法は、糞便等の有機物（タンパク質を含む）存在下においても効果を奏するものである。 The present invention provides a method for erasing genetic information that leads to the reliable inactivation of non-enveloped viruses under conditions where solid residue and white residue are hardly generated after use, and an ethanol preparation that can be used in the method. Can do. Such a method is effective even in the presence of organic matter (including protein) such as feces.
本発明に用いられるエタノール製剤（以下、本発明のエタノール製剤ともいう）は、各有効成分の含有量およびｐＨが以下の（ａ）〜（ｅ）であるエタノール含有組成物である。
（ａ）乳酸またはその塩の含有量が、乳酸として１．０〜１．８重量％である
（ｂ）クエン酸またはその塩の含有量が、クエン酸として０．２〜０．５重量％である
（ｃ）乳酸またはその塩とクエン酸またはその塩の重量比が、乳酸とクエン酸として４：１である
（ｄ）ｐＨが、ｐＨ３〜４である
（ｅ）エタノール濃度が、６５重量％以上、７５重量％未満であるThe ethanol preparation used in the present invention (hereinafter also referred to as the ethanol preparation of the present invention) is an ethanol-containing composition in which the content and pH of each active ingredient are the following (a) to (e).
(A) The content of lactic acid or a salt thereof is 1.0 to 1.8% by weight as lactic acid. (B) The content of citric acid or a salt thereof is 0.2 to 0.5% by weight as citric acid. (C) The weight ratio of lactic acid or its salt to citric acid or its salt is 4: 1 as lactic acid and citric acid (d) pH is pH 3-4 (e) Ethanol concentration is 65 weight % Or more and less than 75% by weight
本発明のエタノール製剤における乳酸またはその塩およびクエン酸またはその塩の塩としては、ナトリウム塩、カリウム塩、リチウム塩等があげられる。
本発明のエタノール製剤の調製において乳酸およびクエン酸は、その一部に塩を用いることにより、緩衝作用が働いてｐＨの調整が容易になる場合もある。
本発明のエタノール製剤における乳酸またはその塩およびクエン酸またはその塩の含有量は、それぞれ乳酸およびクエン酸として４：１であれば上記数値範囲のいずれの濃度でもよい。Examples of lactic acid or a salt thereof and citric acid or a salt thereof in the ethanol preparation of the present invention include sodium salt, potassium salt, lithium salt and the like.
In the preparation of the ethanol preparation of the present invention, lactic acid and citric acid may have a buffering action by using a salt as a part thereof, and pH adjustment may be facilitated.
The content of lactic acid or a salt thereof and citric acid or a salt thereof in the ethanol preparation of the present invention may be any concentration within the above numerical range as long as it is 4: 1 as lactic acid and citric acid, respectively.
本発明のエタノール製剤のｐＨはｐＨ３〜４のいずれでもよいが、金属への使用の際の腐食をできるだけ抑えることと薬効の強さとのバランスを考慮し、ｐＨ３．４〜３．７であることが好ましい。
本発明のエタノール製剤におけるエタノール濃度は６５重量％以上７５重量％未満のいずれでもよいが、薬効の強さから６８〜７２重量％であることが好ましく、６８〜７０重量％であることがより好ましい。The pH of the ethanol preparation of the present invention may be any of pH 3 to 4, but it should be pH 3.4 to 3.7 in consideration of the balance between suppressing corrosion when used on metals as much as possible and the strength of medicinal properties. Is preferred.
The ethanol concentration in the ethanol preparation of the present invention may be any of 65% by weight or more and less than 75% by weight, but is preferably 68 to 72% by weight, more preferably 68 to 70% by weight from the strength of medicinal effect. .
有効成分の含有量およびｐＨが上記条件を満たすエタノール製剤は、ノンエンベロープウイルスの遺伝情報を消失させるに十分な活性を奏する。したがって、本発明のエタノール製剤は、有効成分との塩の形成により溶解性を悪くする恐れがある亜鉛含有化合物等の他の有効成分を含有する必要は特にない。しかし、本発明のエタノール製剤の薬効が妨げられない限り、必要に応じてポリグリセリン脂肪酸エステル、グリセリン脂肪酸エステル、ヒアルロン酸、グリセリン等の保湿剤や色素、香料等を含有してもよい。特にポリグリセリン脂肪酸エステルは、これを含有することにより、エタノール製剤の表面張力が低下し、接触面積が広くなる。また、細かい隙間にも浸透しやすくなるため、本発明のエタノール製剤の薬効が高まることが期待できる。 An ethanol preparation in which the content and pH of the active ingredient satisfy the above conditions exhibits sufficient activity to eliminate the genetic information of the non-enveloped virus. Therefore, the ethanol preparation of the present invention does not need to contain other active ingredients such as a zinc-containing compound that may deteriorate the solubility due to the formation of a salt with the active ingredient. However, a moisturizer such as polyglycerin fatty acid ester, glycerin fatty acid ester, hyaluronic acid, and glycerin, a coloring agent, a fragrance, and the like may be included as necessary as long as the medicinal effect of the ethanol preparation of the present invention is not hindered. In particular, the polyglycerol fatty acid ester contains this, whereby the surface tension of the ethanol preparation is lowered and the contact area is increased. Moreover, since it becomes easy to penetrate into fine gaps, it can be expected that the medicinal effect of the ethanol preparation of the present invention is increased.
ポリグリセリン脂肪酸エステルの好適な例としては、ラウリン酸テトラグリセリル、ラウリン酸ペンタグリセリル、ラウリン酸ヘキサグリセリル等を挙げることができる。
ポリグリセリン脂肪酸エステルの含有量は本発明のエタノール製剤の薬効を妨げない限り限定されないが、通常０．０１〜０．１重量％である。Preferable examples of the polyglycerol fatty acid ester include tetraglyceryl laurate, pentaglyceryl laurate, hexaglyceryl laurate and the like.
The content of the polyglycerol fatty acid ester is not limited as long as it does not interfere with the medicinal effect of the ethanol preparation of the present invention, but is usually 0.01 to 0.1% by weight.
本発明のエタノール製剤は、例えば乳酸またはその塩およびクエン酸またはその塩、および必要に応じてポリグリセリン脂肪酸エステル等を上記濃度となるようにエタノール水に溶解させ、エタノール濃度およびｐＨを上記濃度となるように、酸やアルカリにより調整することにより調製することができるが、各工程の順はこれに限られない。 In the ethanol preparation of the present invention, for example, lactic acid or a salt thereof and citric acid or a salt thereof, and if necessary, a polyglycerol fatty acid ester or the like is dissolved in ethanol water so as to have the above concentration, and the ethanol concentration and pH are adjusted to the above concentrations. Although it can prepare by adjusting with an acid or an alkali so that it may become, the order of each process is not restricted to this.
本発明のエタノール製剤によりノンエンベロープウイルスの遺伝情報を消失させる方法としては、該エタノール製剤とノンエンベロープウイルスとを１分間以上、好ましくは３分間以上、より好ましくは５分間以上接触させる方法があげられる。これらを接触させる方法は、該エタノール製剤をノンエンベロープウイルスの存在が疑われる物に噴霧、塗布、混合させる等、いずれの方法であってもよい。ノンエンベロープウイルスの存在が疑われる物は、固体、液体、気体のいずれであってもよいが、固体である場合、通常の製剤では使用後に固形分の残存によるべたつき、白残り等の好ましくない事象の発生する可能性があるため、本エタノール製剤がその長所を発揮でき、好ましい。固体としては、食器類や食品用機械器具等が好ましくあげられる。 Examples of the method for eliminating genetic information of non-enveloped virus with the ethanol preparation of the present invention include a method of contacting the ethanol preparation with the non-envelope virus for 1 minute or longer, preferably 3 minutes or longer, more preferably 5 minutes or longer. . The method of bringing these into contact with each other may be any method such as spraying, applying, or mixing the ethanol preparation to a substance suspected of having a non-enveloped virus. Substances suspected of having non-enveloped viruses may be solid, liquid, or gas, but in the case of solids, in normal preparations, unfavorable events such as stickiness due to remaining solids after use, white residue, etc. This ethanol preparation is preferable because it can exhibit its advantages. Preferred solids include tableware and food machinery.
ノンエンベロープウイルスの存在が疑われる物が食器類や食品用機械器具である場合は、これらを本発明のエタノール製剤に浸漬することが有効である。浸漬できない場合はこれらの物へ噴霧して使用することもできる。浸漬も噴霧もできない場合は、ダスター等に本発明の組成物を染み込ませて、対象表面を拭き取って使用することもできる。
本発明の方法を実施した後にノンエンベロープウイルスの遺伝情報が消失していることは、ＰＣＲ法等のＤＮＡまたはＲＮＡの存在を検出できる方法により確認することができる。When the thing in which existence of non-enveloped virus is suspected is tableware or food machinery, it is effective to immerse these in the ethanol preparation of the present invention. When it cannot be immersed, it can also be used by spraying on these items. When neither immersion nor spraying can be performed, the composition of the present invention can be soaked in a duster or the like, and the target surface can be wiped off.
The disappearance of the genetic information of the non-enveloped virus after the method of the present invention can be confirmed by a method capable of detecting the presence of DNA or RNA, such as a PCR method.
上記のとおり、本発明のエタノール製剤は、抗ノンエンベロープウイルス用のエタノール製剤として好適に用いることができる。
本発明におけるノンエンベロープウイルスとしては、ＲＮＡを遺伝情報の担体とするノロウイルス（Ｎｏｒｏｖｉｒｕｓ）等のカリシウイルス科（Ｃａｌｉｃｉｖｉｒｉｄａｅ）、ロタウイルス（Ｒｏｔａｖｉｒｕｓ）等のレオウイルス科（Ｒｅｏｖｉｒｉｄａｅ）、エンテロウイルス（Ｅｎｔｅｒｏｖｉｒｕｓ）等のピコナウイルス（Ｐｉｃｏｒｎａｖｉｒｉｄａｅ）科等に属するＲＮＡウイルス、およびＤＮＡを遺伝情報の担体とするアデノウイルス（Ａｄｅｎｏｖｉｒｉｄａｅ）科に属するＤＮＡウイルスがあげられるが、ＲＮＡウイルスが好ましくあげられる。
以下に本発明の実施例をあげるが、本発明はこれらの実施例に限定されるものではない。As described above, the ethanol preparation of the present invention can be suitably used as an ethanol preparation for anti-non-enveloped viruses.
Non-enveloped viruses in the present invention include, for example, Noroviruses such as Norovirus, which uses RNA as a carrier of genetic information, Reoviridae such as Rotavirus, Reoviridae, Enterovirus, etc. RNA viruses belonging to the Piconaviridae family and the like, and DNA viruses belonging to the Adenoviridae family using DNA as a carrier of genetic information are preferred, and RNA viruses are preferred.
Examples of the present invention will be given below, but the present invention is not limited to these examples.
ＧＩＩ／４型ノロウイルスに感染した患者の便（Ａ〜Ｃ）を採取した。
便Ａよりタンパク質等を除去し、ウイルス液Ａ（ＰＥＧ濃縮液）を調製した。
また、便ＢおよびＣを、それぞれ蒸留水で１０倍希釈し、ウイルス液Ｂ−１、Ｂ−２、およびＣを調製した。なお、ウイルス液Ｂ−１およびＢ−２は、同一の便材料の異なる箇所から採集したものであるため、このような表記としている。
各ウイルス液中のウイルス粒子数は、いずれも約１０７個／ｍｌである。
一方、表１記載の組成のエタノール製剤（実施例１〜３および比較例１〜３）を調製した。Feces (AC) of patients infected with GII / 4 type Norovirus were collected.
Proteins and the like were removed from stool A to prepare virus solution A (PEG concentrated solution).
In addition, feces B and C were each diluted 10-fold with distilled water to prepare virus solutions B-1, B-2, and C. In addition, since the virus liquids B-1 and B-2 are collected from different parts of the same fecal material, they are represented as such.
The number of virus particles in each virus solution is about 10 7 particles / ml.
On the other hand, ethanol formulations (Examples 1 to 3 and Comparative Examples 1 to 3) having the composition described in Table 1 were prepared.
調製したウイルス液２０μｌとエタノール製剤１８０μｌとを混合し１０分間室温で静置後、２００μｌの普通ブイヨンを加えてエタノール製剤の作用を停止させた。
この溶液をウイルスのエタノール製剤による処理液として、ＭａｇＥｘｔｒａｃｔｏｒ ＶｉｒａｌＲＮＡキット（東洋紡社製）を用いてＲＮＡを抽出した。得られたＲＮＡと逆転写酵素（ＲｅｖｅｒＴｒａ Ａｃｅ：東洋紡社製）とを４２℃で６０分間反応させてｃＤＮＡを調製した（変性温度９９℃ ５分間）。得られたｃＤＮＡを鋳型とし、ヒトノロウイルス検出用のプライマーとして周知であるＧ２−ＳＫＦプライマーおよびＧ２−ＳＫＲプライマーを用い、リアルタイムＰＣＲ装置（ＳｔｅｐＯｎｅ Ｐｌｕｓ：Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍ社製）でリアルタイムＰＣＲを行ってウイルスのエタノール製剤による処理液中のＲＮＡのコピー数を算出した。20 μl of the prepared virus solution and 180 μl of ethanol preparation were mixed and allowed to stand at room temperature for 10 minutes, and then 200 μl of normal bouillon was added to stop the action of the ethanol preparation.
Using this solution as a treatment solution with a virus ethanol preparation, RNA was extracted using MagExtractor ViralRNA kit (manufactured by Toyobo Co., Ltd.). The obtained RNA was reacted with reverse transcriptase (ReverTra Ace: manufactured by Toyobo Co., Ltd.) at 42 ° C. for 60 minutes to prepare cDNA (denaturation temperature 99 ° C. for 5 minutes). Using the obtained cDNA as a template, using the G2-SKF primer and G2-SKR primer, which are well-known as primers for detecting human norovirus, real-time PCR is performed with a real-time PCR apparatus (Step One Plus: Applied Biosystem) to detect the virus. The number of RNA copies in the treatment solution with the ethanol preparation was calculated.
また、ウイルス液をエタノール製剤で処理する代わりに、次亜塩素酸ナトリウム溶液を終濃度５４，０００ｐｐｍとなるようにウイルス液（Ａ〜Ｃ）に添加して処理する以外は同様の操作を行い、ウイルスの次亜塩素酸ナトリウムによる処理液中のＲＮＡのコピー数を算出した。
予め測定しておいた薬剤処理する前のウイルス液中のＲＮＡのコピー数と、薬剤処理した後のウイルス液中のＲＮＡのコピー数とから、ウイルス液中のＲＮＡの減少率を算出した。結果を表２に示す。In addition, instead of treating the virus solution with an ethanol preparation, the same operation was performed except that the sodium hypochlorite solution was added to the virus solution (A to C) so as to have a final concentration of 54,000 ppm. The number of RNA copies in the solution treated with viral sodium hypochlorite was calculated.
The reduction rate of RNA in the virus solution was calculated from the RNA copy number in the virus solution before drug treatment and the RNA copy number in the virus solution after drug treatment, which were measured in advance. The results are shown in Table 2.
表２に示すとおり、本発明のエタノール製剤に該当する実施例１〜３のエタノール製剤は、タンパク等を除去したウイルス液（ウイルス液Ａ）のみならず、有機物を含有するウイルス液（ウイルス液Ｂ−１、Ｂ−２およびＣ）においても優れたＲＮＡ消失効果を示した。これに対し、本発明のエタノール製剤の条件を満たさない比較例１〜３のエタノール製剤および次亜塩素酸ナトリウムを用いて処理したウイルス液では効果にバラつきが認められた。ちなみに、エタノール製剤の代わりに、エタノール系消毒薬として広く用いられている７０重量％のエタノール水溶液で同様な処理を行ったところ、残存率は約５０％であって高い効果は得られなかった。 As shown in Table 2, the ethanol preparations of Examples 1 to 3 corresponding to the ethanol preparation of the present invention are not only a virus solution (virus solution A) from which proteins and the like have been removed, but also a virus solution (virus solution B) containing an organic substance. -1, B-2 and C) also showed an excellent RNA elimination effect. On the other hand, variation was recognized in the effect of the virus solution treated with the ethanol preparations of Comparative Examples 1 to 3 and sodium hypochlorite that did not satisfy the conditions of the ethanol preparation of the present invention. By the way, when the same treatment was performed with a 70 wt% aqueous ethanol solution widely used as an ethanol-based disinfectant instead of the ethanol preparation, the residual rate was about 50%, and a high effect was not obtained.
表３記載の組成のエタノール製剤を調製した。ｐＨはいずれもｐＨ３．２に統一した。エタノール濃度（５５％）は本発明のエタノール製剤のエタノール濃度の範囲外であるが、これはエタノール蒸散による影響を統一するためである。また、総酸量は製剤２を除きほぼ同一である。 Ethanol preparations having the composition described in Table 3 were prepared. All pH was unified to pH 3.2. The ethanol concentration (55%) is outside the range of the ethanol concentration of the ethanol preparation of the present invention, which is to unify the influence of ethanol evaporation. The total acid amount is almost the same except for Formulation 2.
（１）それぞれのステンレス板に各製剤を１ｍｌ噴霧し、３０℃で５日間放置した。５日間経過後、ステンレス板の腐食度合い、および薬剤中の成分による白残り、液残りの度合いを表４に示した。(1) 1 ml of each preparation was sprayed on each stainless steel plate and left at 30 ° C. for 5 days. Table 5 shows the degree of corrosion of the stainless steel plate and the degree of white residue and liquid residue due to the components in the chemical after 5 days.
表４に示したとおり、乳酸とクエン酸とを４：１で含有するエタノール製剤１では、エタノールは完全に蒸散し、成分の白残りも認められなかった。これに対して、製剤１と総酸量がほぼ同一であるが成分の量比が異なる製剤３〜６では成分の白残りや液残りが認められた。また、リン酸を含有する製剤２ではステンレス版の腐食がかなり認められた。
（２）それぞれのステンレス板に各製剤を１ｍｌ噴霧し、３０℃で６時間放置した。その後、噴霧部を紙で拭き取り、再度３０℃で２日間放置した。２日後、ステンレス板の腐食、白残り、べたつきの度合いを評価した。結果を表５に示す。As shown in Table 4, in the ethanol preparation 1 containing lactic acid and citric acid at a ratio of 4: 1, ethanol was completely evaporated and no white residue was observed. On the other hand, in the preparations 3 to 6 in which the total acid amount was almost the same as that of the preparation 1, but the amount ratios of the components were different, white residues and liquid residues of the components were observed. Further, in the preparation 2 containing phosphoric acid, corrosion of the stainless plate was considerably observed.
(2) 1 ml of each preparation was sprayed on each stainless steel plate and left at 30 ° C. for 6 hours. Thereafter, the sprayed part was wiped off with paper and left again at 30 ° C. for 2 days. Two days later, the degree of corrosion, white residue, and stickiness of the stainless steel plate was evaluated. The results are shown in Table 5.
表５に示すとおり、乳酸とクエン酸とを４：１で含有するエタノール製剤１では、成分の白残りやべたつきが認められなかった。これに対して、製剤１と総酸量がほぼ同一であるが成分の量比が異なる製剤３〜６では成分の白残りやべたつきが認められた。また、リン酸を含有する製剤２ではステンレス版の腐食がかなり認められた。 As shown in Table 5, in the ethanol preparation 1 containing lactic acid and citric acid at a ratio of 4: 1, no white residue or stickiness of the components was observed. On the other hand, in the preparations 3 to 6 in which the total acid amount was almost the same as that of the preparation 1, but the amount ratios of the components were different, white residue and stickiness of the components were recognized. Further, in the preparation 2 containing phosphoric acid, corrosion of the stainless plate was considerably observed.
本発明により、使用後に固形分の残存によるべたつき、白残り等が発生しにくい条件で、ノンエンベロープウイルスの遺伝情報を消失させる方法および該方法に用い得るエタノール製剤を提供することができる。ノンエンベロープウイルスの遺伝情報の消失は該ウイルスの確実な不活化にとって重要である。係る方法は、糞便等の有機物（タンパク質を含む）存在下においても効果を奏するものであり、実用性が高い。 INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a method for eliminating genetic information of a non-enveloped virus and an ethanol preparation that can be used in the method under conditions where stickiness due to residual solids, white residue, and the like hardly occur after use. Loss of non-enveloped virus genetic information is important for reliable inactivation of the virus. Such a method is effective even in the presence of organic matter (including protein) such as feces, and is highly practical.
Claims (2)
（ａ）乳酸またはその塩の含有量が、乳酸として１．０〜１．８重量％である
（ｂ）クエン酸またはその塩の含有量が、クエン酸として０．２〜０．５重量％である
（ｃ）乳酸またはその塩とクエン酸またはその塩の重量比が、乳酸とクエン酸として４：１である
（ｄ）ｐＨが、ｐＨ３〜４である
（ｅ）エタノール濃度が、６５重量％以上、７５重量％未満であるA method for eliminating genetic information of a non-enveloped virus, which comprises contacting an ethanol preparation having a content and pH of each active ingredient below (a) to (e) with the non-enveloped virus.
(A) The content of lactic acid or a salt thereof is 1.0 to 1.8% by weight as lactic acid. (B) The content of citric acid or a salt thereof is 0.2 to 0.5% by weight as citric acid. (C) The weight ratio of lactic acid or its salt to citric acid or its salt is 4: 1 as lactic acid and citric acid (d) pH is pH 3-4 (e) Ethanol concentration is 65 weight % Or more and less than 75% by weight
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015217969A JP6688597B2 (en) | 2015-10-20 | 2015-10-20 | Method for eliminating genetic information of non-enveloped virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015217969A JP6688597B2 (en) | 2015-10-20 | 2015-10-20 | Method for eliminating genetic information of non-enveloped virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017077232A true JP2017077232A (en) | 2017-04-27 |
| JP6688597B2 JP6688597B2 (en) | 2020-04-28 |
Family
ID=58665006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015217969A Active JP6688597B2 (en) | 2015-10-20 | 2015-10-20 | Method for eliminating genetic information of non-enveloped virus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6688597B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019073453A (en) * | 2017-10-12 | 2019-05-16 | Ｍｃフードスペシャリティーズ株式会社 | Antimicrobial composition which suppresses viruses, bacteria, and fungi |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008255101A (en) * | 2007-03-09 | 2008-10-23 | Maruishi Pharmaceutical Co Ltd | Disinfectant |
| WO2008153077A1 (en) * | 2007-06-12 | 2008-12-18 | Hiroshima University | Anti-norovirus agent, and composition comprising the same |
| JP2009173641A (en) * | 2007-12-27 | 2009-08-06 | Johnson Diversey Co Ltd | Bactericidal disinfectant composition, bactericidal disinfectant material comprising the same, and bactericidal disinfection method using the same composition or the same material |
| WO2010047108A1 (en) * | 2008-10-24 | 2010-04-29 | メルシャン株式会社 | Calicivirus inactivation method |
| JP2012140337A (en) * | 2010-12-28 | 2012-07-26 | Kao Corp | Cosmetic-containing sheet |
| JP2014019659A (en) * | 2012-07-13 | 2014-02-03 | Niitaka:Kk | Disinfection liquid and disinfection method |
| JP2017071585A (en) * | 2015-10-09 | 2017-04-13 | 国立大学法人広島大学 | Anti-norovirus agent |
-
2015
- 2015-10-20 JP JP2015217969A patent/JP6688597B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008255101A (en) * | 2007-03-09 | 2008-10-23 | Maruishi Pharmaceutical Co Ltd | Disinfectant |
| WO2008153077A1 (en) * | 2007-06-12 | 2008-12-18 | Hiroshima University | Anti-norovirus agent, and composition comprising the same |
| JP2009173641A (en) * | 2007-12-27 | 2009-08-06 | Johnson Diversey Co Ltd | Bactericidal disinfectant composition, bactericidal disinfectant material comprising the same, and bactericidal disinfection method using the same composition or the same material |
| WO2010047108A1 (en) * | 2008-10-24 | 2010-04-29 | メルシャン株式会社 | Calicivirus inactivation method |
| JP2012140337A (en) * | 2010-12-28 | 2012-07-26 | Kao Corp | Cosmetic-containing sheet |
| JP2014019659A (en) * | 2012-07-13 | 2014-02-03 | Niitaka:Kk | Disinfection liquid and disinfection method |
| JP2017071585A (en) * | 2015-10-09 | 2017-04-13 | 国立大学法人広島大学 | Anti-norovirus agent |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019073453A (en) * | 2017-10-12 | 2019-05-16 | Ｍｃフードスペシャリティーズ株式会社 | Antimicrobial composition which suppresses viruses, bacteria, and fungi |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6688597B2 (en) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5829293B2 (en) | Calicivirus inactivation method | |
| JP2009292736A (en) | Anti-norovirus composition | |
| JP5832201B2 (en) | Norovirus composition | |
| JP6783516B2 (en) | Composition having calicivirus inactivating effect | |
| CN108605933A (en) | A kind of fatty acid complexes | |
| JP6704099B1 (en) | Sterilizing or virus inactivating agent composition, and method for enhancing efficacy of sterilizing or virus inactivating agent | |
| JP6531234B1 (en) | Virus inactivating agent, norovirus inactivating agent and hygiene material | |
| JP5158352B2 (en) | Antiviral agent | |
| JP6688597B2 (en) | Method for eliminating genetic information of non-enveloped virus | |
| JP5837346B2 (en) | Virus inactivating composition | |
| JP7058490B2 (en) | Antibacterial composition that suppresses viruses, bacteria and fungi | |
| JP6889925B2 (en) | Virus inactivating agents, norovirus inactivating agents and sanitary materials | |
| JP6688929B1 (en) | Disinfectant composition, sanitary material, food cleaning agent, and food preservative | |
| JP2019052107A (en) | Bactericidal and virus inactivation agent and bactericidal and virus inactivation method | |
| CN113473858A (en) | Bactericidal or viral inactivating agent composition and method for enhancing bactericidal or viral inactivating efficacy | |
| JP2021155368A (en) | Bacteriocidal/virus-inactivating composition | |
| JP2020033279A (en) | Anti-norovirus agent, disinfectant and cleaning agent | |
| JP2022125090A (en) | Virus deactivation composition | |
| JP5377098B2 (en) | Norovirus inactivating agent | |
| JP6585756B2 (en) | Virus inactivators, norovirus inactivators and hygiene materials | |
| JP7450247B2 (en) | anti-enterovirus agent | |
| JP2016117693A (en) | Water-soluble composition having antibacterial and antivirus property | |
| JP2016216430A (en) | Alcohol preparation for aluminum, sterilization method | |
| JP7168993B2 (en) | Virus inactivator, norovirus inactivator and sanitary materials | |
| JP2018197205A (en) | Virus deactivator, norovirus deactivator and sanitary material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181015 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200403 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200406 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6688597 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |